登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，4月2日，Why inequality could spread COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-03

  • Why inequality could spread COVID-19

    Faheem Ahmed

    Na'eem Ahmed

    Christopher Pissarides

    Joseph Stiglitz

    Open AccessPublished:April 02, 2020DOI:https://doi.org/10.1016/S2468-2667(20)30085-2

    Pandemics rarely affect all people in a uniform way. The Black Death in the 14th century reduced the global population by a third, with the highest number of deaths observed among the poorest populations.1 Densely populated with malnourished and overworked peasants, medieval Europe was a fertile breeding ground for the bubonic plague. Seven centuries on—with a global gross domestic product of almost US$100 trillion—is our world adequately resourced to prevent another pandemic?2 Current evidence from the coronavirus disease 2019 (COVID-19) pandemic would suggest otherwise.

  • 原文来源：https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30085-2/fulltext
127浏览量
原文链接
相关报告

  • 《LANCET，4月3日，Baricitinib for COVID-19: a suitable treatment? – Authors' reply》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-04
    • Baricitinib for COVID-19: a suitable treatment? – Authors' reply Peter J Richardson，Mario Corbellino，Justin Stebbing Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30270-X We thank Ennio Favalli and colleagues for their Correspondence regarding our suggestion to use baricitinib for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.1, 2 We also appreciate their recognition that inhibition of numb-associated kinase enzymes could indeed be beneficial in preventing virus infectivity via inhibition of clathrin-mediated endocytosis. We welcome the opportunity to more fully explain the possible use of baricitinib in the current pandemic. Indeed, we accept that using a JAK1 and JAK2 inhibitor to treat a viral disease might appear illogical given that the antiviral effects of interferons are largely mediated by the JAK–STAT signalling pathway. However, the administration of pegylated-interferon has not had the beneficial antiviral effects originally hoped for,4 and clinical trials with interferons have yielded inconsistent results, with pathogenic effects of interferons being observed in some viral infections.
    159浏览量
    原文链接

  • 《LANCET，4月2日，Monitoring the COVID-19 epidemic in the context of widespread local transmission》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-05
    • Monitoring the COVID-19 epidemic in the context of widespread local transmission Alberto L García-Basteiro Carlos Chaccour Caterina Guinovart Anna Llupià Joe Brew Antoni Trilla et al. Published:April 02, 2020DOI:https://doi.org/10.1016/S2213-2600(20)30162-4 Coronavirus disease 2019 (COVID-19) is a novel viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first detected in Wuhan, China, in December, 2019.1 Given the fast spread, the severity of disease, the increasing number of cases outside China, and the number of affected countries, WHO declared the rapid spread of SARS-CoV-2 a pandemic on March 11, 2020.2 The availability of reliable surveillance platforms is crucial to monitor the COVID-19 epidemic in a timely manner and to respond with adequate control measures. Since the beginning of the outbreak, different countries have used different testing approaches and criteria, depending on their resources and capacity.
    30浏览量
    原文链接